Article (Scientific journals)
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Fogelman, I; Ribot, C; Smith, R et al.
2000In Journal of Clinical Endocrinology and Metabolism, 85 (5), p. 1895-900
Peer Reviewed verified by ORBi
 

Files


Full Text
Risedronate reverses bone loss in postmenopausal women with low bone mass.pdf
Publisher postprint (683.16 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Aged; Bone Density/drug effects; Calcium/therapeutic use; Calcium Channel Blockers/adverse effects/therapeutic use; Double-Blind Method; Etidronic Acid/adverse effects/analogs & derivatives/therapeutic use; Europe; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal/drug therapy; Placebos; Time Factors
Abstract :
[en] Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass. Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months of placebo or risedronate (2.5 or 5 mg/day). All received calcium (1 g/day). The principal outcome measures were bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter. At 24 months, lumbar spine BMD increased from baseline by 4% with 5 mg risedronate and 1.4% in the 2.5-mg group, compared with no change with placebo. Efficacy was similar in women who were less than 5 yr and more than 5 yr postmenopausal. At 24 months, risedronate (5 mg) had also increased BMD at the femoral neck and trochanter, whereas BMD decreased in the placebo group. BMD increases were seen at all three sites with risedronate (5 mg) after only 6 months of therapy. Risedronate was well tolerated; upper gastrointestinal adverse events were similar to placebo. We conclude that risedronate (5 mg) increases BMD rapidly and effectively and is well tolerated in postmenopausal women with low bone mass, regardless of time since menopause.
Disciplines :
General & internal medicine
Author, co-author :
Fogelman, I
Ribot, C
Smith, R
Ethgen, D
Sod, E
REGINSTER, Jean-Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Language :
English
Title :
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Publication date :
2000
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Volume :
85
Issue :
5
Pages :
1895-900
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 21 June 2012

Statistics


Number of views
56 (1 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
199
Scopus citations®
without self-citations
191
OpenCitations
 
44

Bibliography


Similar publications



Contact ORBi